Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System Disorders

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 50
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

This is an observational, retro-prospective, moncentric study focused on Inborn Errors of Immunity, an heterogeneous group of inherited diseases due to defects in the differentiation and/or function of the immune system. The primary aim of this study is to obtain a clinical-immunological, functional and molecular characterisation of paediatric and adult patients with confirmed or suspected Inborn Errors of Immunity, particularly of patients with manifestations of immunedysregulation, focusing on clinical course, immunophenotypic laboratory and functional abnormalities, genetic background.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients with confirmed or suspected Inborn Errors of Immunity;

age < 50 years at onset of clinical features suspected for Inborn Errors of Immunity;

obtaining informed consent from patients or parents/legal guardian of pediatric patients.

Disqualifiers

None

Trial population

Patients with confirmed or suspected Inborn Errors of Immunity, in particular patients with an immunodysregulated condition (autoimmunity, allergy, hyperinflammation and non-clonal lymphoproliferation, susceptibility to the development of malignant neoplasms) aged \< 50 years at onset of clinical features suspected for Inborn Errors of Immunity, who referred to the Pediatrics Unit of the IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola, Italy.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Category of diagnsoed Inborn Error of Immunity

categories I to X

Time frame
at baseline
2

Qualitative or quantitative alterations in innate immunity and/or adaptive immunity

presence or absence of alterations

Time frame
at baseline
3

Infective susceptibility

presence of one of the following conditions: invasive, severe, persistent, recurrent, opportunistic and/or vaccine strain infections

Time frame
at baseline and every 6 months up to 1 year
4

Immunodisregulation

presence of at least one disorder among atopy, hyperinflammation, autoimmunity, non-clonal lymphoproliferation and/or malignant neoplasms

Time frame
at baseline and every 6 months up to 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.